KR102717599B1 - 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 - Google Patents

치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 Download PDF

Info

Publication number
KR102717599B1
KR102717599B1 KR1020207025729A KR20207025729A KR102717599B1 KR 102717599 B1 KR102717599 B1 KR 102717599B1 KR 1020207025729 A KR1020207025729 A KR 1020207025729A KR 20207025729 A KR20207025729 A KR 20207025729A KR 102717599 B1 KR102717599 B1 KR 102717599B1
Authority
KR
South Korea
Prior art keywords
adm
dementia
subject
adrenomedullin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207025729A
Other languages
English (en)
Korean (ko)
Other versions
KR20200135947A (ko
Inventor
올레 멜란데르
Original Assignee
스핑고텍 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스핑고텍 게엠베하 filed Critical 스핑고텍 게엠베하
Publication of KR20200135947A publication Critical patent/KR20200135947A/ko
Application granted granted Critical
Publication of KR102717599B1 publication Critical patent/KR102717599B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
KR1020207025729A 2018-02-08 2019-02-07 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 Active KR102717599B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155682.0 2018-02-08
EP18155682 2018-02-08
PCT/EP2019/052982 WO2019154900A1 (en) 2018-02-08 2019-02-07 Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia

Publications (2)

Publication Number Publication Date
KR20200135947A KR20200135947A (ko) 2020-12-04
KR102717599B1 true KR102717599B1 (ko) 2024-10-14

Family

ID=61188647

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025729A Active KR102717599B1 (ko) 2018-02-08 2019-02-07 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제

Country Status (12)

Country Link
US (2) US20210302440A1 (enExample)
EP (1) EP3749959A1 (enExample)
JP (2) JP2021513077A (enExample)
KR (1) KR102717599B1 (enExample)
CN (2) CN119770645A (enExample)
AU (1) AU2019219071A1 (enExample)
BR (1) BR112020014940A2 (enExample)
CA (1) CA3090736A1 (enExample)
IL (1) IL276564A (enExample)
MX (1) MX421834B (enExample)
SG (1) SG11202006686SA (enExample)
WO (1) WO2019154900A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
US20230097988A1 (en) 2020-02-26 2023-03-30 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
IL295924A (en) 2020-02-26 2022-10-01 Pam Theragnostics Gmbh Use of peptidylglycine alpha-amidization monooxygenase (pam) for medicinal purposes
AU2021238591A1 (en) 2020-03-16 2022-11-17 Adrenomed Ag Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin
JP2026510789A (ja) 2023-03-17 2026-04-10 ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用
WO2025133203A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062463A1 (en) * 2006-06-16 2010-03-11 B.R.A.H.M.S Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative disorders
US20110039343A1 (en) * 2008-02-01 2011-02-17 Brahms Aktiengesellschaft Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
US20140322824A1 (en) 2011-11-16 2014-10-30 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US20090306227A1 (en) 2005-08-31 2009-12-10 Toshiyuki Ioka Tablet for removing tongue coating
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
IL283215B2 (en) * 2011-11-16 2024-05-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
US20160230227A1 (en) * 2012-12-21 2016-08-11 The New York Stem Cell Foundation Methods of treating alzheimer's disease
RU2019103403A (ru) * 2016-07-08 2020-08-10 Сфинготек Гмбх Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062463A1 (en) * 2006-06-16 2010-03-11 B.R.A.H.M.S Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative disorders
US20110039343A1 (en) * 2008-02-01 2011-02-17 Brahms Aktiengesellschaft Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
US20140322824A1 (en) 2011-11-16 2014-10-30 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin

Also Published As

Publication number Publication date
SG11202006686SA (en) 2020-08-28
MX2020008345A (es) 2020-09-25
KR20200135947A (ko) 2020-12-04
US20230221339A1 (en) 2023-07-13
RU2020129154A3 (enExample) 2022-03-10
MX421834B (es) 2025-03-14
IL276564A (en) 2020-09-30
CN119770645A (zh) 2025-04-08
AU2019219071A1 (en) 2020-07-30
EP3749959A1 (en) 2020-12-16
RU2020129154A (ru) 2022-03-10
US20210302440A1 (en) 2021-09-30
JP2024001208A (ja) 2024-01-09
CN111902721B (zh) 2024-12-13
JP2021513077A (ja) 2021-05-20
CN111902721A (zh) 2020-11-06
WO2019154900A1 (en) 2019-08-15
BR112020014940A2 (pt) 2020-12-08
CA3090736A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
KR102717599B1 (ko) 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
JP7654597B2 (ja) 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン
JP6336911B2 (ja) アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
RU2727022C2 (ru) Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений
US20220268761A1 (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
JP2025530718A (ja) 抗タウｍｔｂｒ抗体、ならびにタウの切断された断片の検出方法およびその用途
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
US20230357383A1 (en) Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C
RU2811309C2 (ru) Адреномедуллин (adm) для диагностики и/или прогнозирования деменции и антиадреномедуллин-связующий агент для применения в терапии или профилактике деменции
US20180156822A1 (en) Biomarker for cardiac disorders
HK40121614A (zh) 用於诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
HK40034157A (en) Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
RU2776811C2 (ru) Мониторинг терапии при лечении связывающим веществом против адреномедуллина (adm)
EA049359B1 (ru) Анализ проб, полученных из крови, для обнаружения таупатии или амилоидогенного заболевания
HK40005377B (zh) 肾上腺髓质素用於评估急性心力衰竭患者的充血
HK1202624B (en) Adrenomedullin assays and methods for determining mature adrenomedullin
HK40005377A (en) Adrenomedullin for assessing congestion in a subject with acute heart failure

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200907

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231108

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240905

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241010

End annual number: 3

Start annual number: 1

PG1601 Publication of registration